A very proactive patient in the UK suffering from Crohn`s disease wanted to share the story of his use of IBDoc® after one year. For the past 27 years, he tried every kind of medication available. Only a very strict diet based on rice, chicken and carrots associated with a therapeutic monoclonal antibody allowed him to
Continue Reading →
- support@ibdoc.net
- +41 61 487 12 12
- www.buhlmannlabs.ch
Blog Archives
The Mercy University Hospital in Cork was the first hospital to introduce the BÜHLMANN IBDoc® self-testing in routine. After 4 years of use they can show the real benefit of IBDoc® for patients and the clinic. One of their most important finding was the number of unnecessary procedures avoided for patients. On a study of 131
Continue Reading →
At this years ECCO the ECCO IBD guidelines were updated to include a statement to use fecal calprotectin (fCAL) in IBD monitoring. This means that IBD patients will do many calprotectin measurements over their disease course. At the same time as in all chronic disease the therapy follow-up is more and more done remotely decreasing
Fecal calprotectin (fCAL) is a biomarker used for disease monitoring in patients suffering from intestinal bowel disease (IBD) since it correlates closely with mucosal healing. Calprotectin measuring requires patients to collect and return stool samples resulting in relatively low return rate of samples. Home-based fCAL testing may improve adherence. In this post three recent publications
Read a recent interview with Lead Inflammatory Bowel Disease Nurse, Pearl Avery, conducted by BÜHLMANN’s UK distributor Alpha Laboratories Highlight the Article: “In the six months that we have been working with the IBDoc®, one patient was saved from hospital admission. It looked like they were having an IBD flare but the symptoms were actually
At this year’s SwissMedtech Day, BÜHLMANN was nominated to receive the Swiss Medtech Award. Switzerland is listed by key rankings as the “globally most innovative country”. Medtech one of the industries heavily contributing to this ranking. Out of 25 applications BÜHLMANN Laboratories AG was chosen to present IBDoc® to a Jury of medtech and academic
Pearl Avery, UK IBD Nurse of the year, shares her first experience using IBDoc® in clinical practice. She explains the study she published at ECCO 2018 in Vienna in this video:
Tactio Health Group and Telia Company team up to accelerate the development of patient-centred digital health programs in Sweden and other Nordic and Baltic countries. The Swedish telecommunication company Telia, together with AbbVie Sweden, developed the IBD Home platform using the TactioRPM platform. IBD Home is a complete IBD remote monitoring ecosystem. The IBD Home app
Read a recent post from Amanda Appleton, the Product Manager for Calprotectin at our UK distributor Alpha Laboratories. She ends the article with following sentence: “App technology has the ability not only to improve the health of patients but to save money through rapid optimisation of treatment, enable early interventions through monitoring before conditions get
On 4th December 2017 the National Institute for Health and Care Excellence issued a Medtech Innovation Briefing [MIB132]: ‘Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease’. This describes the innovative aspect that test results can be acted on more quickly than waiting for standard laboratory tests and could help reduce colonoscopies and clinical appointments. Costs may